Polypeptide With Localisation/Targeting Motif TRIZ Cases
- Chimeric Receptor Engineering for Myeloid Cell Phenotype Control
Engineer chimeric receptors to activate myeloid cells, resolving immunosuppression and enhancing anti-tumor immunity.
- Universal Non-Classical MHC I Peptide Vaccines Bypassing Polymorphic HLA Pathways
Non-classical MHC Ib peptide vaccines utilize HLA-E, HLA-F, and HLA-G molecules to present antigens across all human populations.
- Multivalent Monospecific Antibody Assembly via Segmented scFv
Segmented single-chain variable fragments assemble into multispecific complexes, resolving production complexity while retaining Ig function.
- Di-enzymatic Chimeric Endolysin Synergistic Peptidoglycan Cleavage
Merging distinct enzymatic domains into a single chimeric molecule overcomes limited bacteriolytic activity against antibiotic-resistant Gram-positive strains.
- Zika Virus Vaccine Nucleic Acid prM-E Segmentation
Nucleic acid molecules encode Zika virus prM and E proteins for virus-like particle production.
- Serum-Free Media for T Cell Expansion
A chemically defined serum-free medium expands T cell populations using specific nutrient ratios.
- Engineered CARs Targeting T-Cell Malignancies
Segmented CAR designs with specific recognition domains eliminate T-cell leukemia while managing structural complexity.
- MAD2019-H848A Nickase Fusion Proteins for Precise Nucleic Acid Editing
Engineered MAD2019-H848A nickase fusion proteins combine reverse transcriptase activity to enable precise nucleic acid editing.
- Recombinant Virion Arrays for Membrane Protein Profiling
Recombinant virion arrays display human membrane proteins in native conformations for high-throughput screening.
- Yeast Transcription Factor Overexpression for Recombinant Protein Yield
Engineering yeast with Msn4/2 transcription factors to overcome expression bottlenecks and increase recombinant protein titer.
- Pichia pastoris Yeast Expression for Influenza HA Antigen Production
Transient Pichia pastoris expression yields highly immunogenic haemagglutinin antigen without protein contamination or virus contact.
- RMAD1 Human-Derived Peptide for Efficient Cargo Delivery
A human ADARB2-derived RMAD1 peptide enables high-efficiency cargo molecule delivery into cells.
- Furin-Cleavable Delivery Constructs for Epithelial Transport
A furin-cleavable delivery construct uses a transcytosing element to transport therapeutic cargo across epithelial barriers.
- Peptide Accumulation in Cancer Stroma for Drug Delivery
A peptide accumulates in cancer stroma to deliver anticancer drugs.
- Targeted DNA Methylation via CRISPR-PUF Hybrid System
A ribonucleoprotein complex directs demethylation activity to specific genomic loci using a three-component hybrid system.
- Codon-Optimized SARS-CoV-2 DNA Vaccine Signal Peptide
A synthetic plasmid DNA vaccine uses codon optimization and a human IgG2 signal peptide to express the SARS-CoV-2 spike glycoprotein.
- Synthetic Suicide Genetic Circuit for Metabolite Screening
A synthetic suicide genetic circuit uses riboswitches to activate cell death in non-producing strains.
- Recombinant Host Cells Using Multiple Secretion Signals
Recombinant host cells employ multiple distinct secretion signals to direct protein production through separate cellular pathways.
- Gam Protein Fusion Base Editors Reduce Indel Formation
Fusing Gam protein to base editors binds double-stranded DNA breaks and prevents indel formation.
- KIF13B-Derived Peptide Inhibits VEGFR2 Trafficking
A Kinesin-derived Angiogenesis Inhibitor peptide blocks VEGFR2 receptor trafficking to the cell surface.
- Heterodimeric Fc Antibodies with P329G Mutation for CAR-T Recruitment
P329G-modified heterodimeric Fc antibodies bridge tumor antigens and CAR-T cells, reducing off-target toxicity while enhancing anti-cancer efficacy.
- TAT-SNAP-23 Fusion Proteins Inhibit Neutrophil Degranulation
TAT-fusion proteins block SNARE complex formation to inhibit neutrophil degranulation.
- Organelle-Targeted GEVI for Mitochondrial Voltage Measurement
Genetically-encoded voltage indicators resolve the gap in studying internal electrical signals of mitochondria and endoplasmic reticulum membranes.
- Stable TRAIL-Producing Pericytes for Anti-Tumor Therapy
Engineered pericytes stably express soluble TRAIL, resolving toxicity and short half-life issues of recombinant proteins.
- Mutant CD3 Zeta Chain Enhances Low-Affinity Antigen Reactivity
ITAM deletion and spacing optimization in CD3 zeta chains increase cytolytic activity against low-affinity cancer antigens.
- FoxP3-Binding Peptides for Treg Cell Regulation
Chemically modified peptides bind FoxP3 to block Treg immunosuppression, reducing autoimmune disease risk while enhancing antitumor response.
- IL13Rα2-Specific CAR T Cells for Solid Tumor Targeting
Engineering CAR T cells to recognize IL13Rα2 resolves the trade-off between tumor destruction and toxicity to normal tissues.
- IL-10 Modulation of CAR-T Cell Toxicity and Survival
Pegylated IL-10 agents enhance CD8+ T cell function and survival during chimeric antigen receptor therapy.
- Jchain-Specific TCRs for Multiple Myeloma Antigen Escape
Jchain-specific T cell receptors recognize multiple myeloma cells via HLA presentation, preventing antigen escape variants that cause relapse.
- Naïve and Stem Memory T Cell Selection for CAR-T Toxicity Control
Pre-selecting naïve and stem memory T cells expands high-potency populations, reducing severe cytokine release syndrome and neurotoxicity.
- HLA-A2 HPV16 E7 Antigen-Binding Proteins for Targeted Cervical Cancer Therapy
Antigen-binding proteins target HLA-displayed HPV 16 E7 peptides to enable precise molecular recognition of infected cells.
- Engineered Cas9 Nuclease Specificity via Residue Mutations
Targeted mutations in Cas9 residues lower off-target binding affinity while preserving on-target cleavage efficiency for precise genome editing.
- Chimeric Receptor Oligomerization for Controlled Immune Activation
Chimeric transmembrane receptors oligomerize upon extramembrane signal detection to activate intracellular pathways.
- C3 Fusion Protein Production and Purity Optimization
Optimizing ADP-ribosyl transferase C3 fusion protein manufacturing through controlled cultivation and sequential chromatography steps.
- Optimized mRNA for Genome Editing Reducing Immunogenicity
Codon-optimized mRNA encoding Cas9 reduces cytokine elevation while increasing genome editing efficiency.
- Reversed Universal CAR System for Multi-Antigen Targeting
A reversed universal chimeric antigen receptor redirects immune cells using modular adapter molecules to recognize diverse peptide epitope tags.
- PCSK9-Mediated Lysosomal Enzyme Targeting for Pompe Disease
PCSK9 enables lysosomal enzyme targeting to skeletal muscle, resolving poor cellular uptake in Pompe disease.
- Carbonic Anhydrase Fusion Protein Purification via Cellulose Beads
Fusing CBM3 to carbonic anhydrase enables selective capture on cellulose beads, bypassing complex separation steps in plant-based production.
- Engineered Zinc Finger Nucleases for BCL11A Enhancer Targeting
Engineered zinc finger nucleases target BCL11A enhancer sequences to reduce off-target cleavage and sustain gamma globin expression.
- Optogenetic Protein Clustering for Genomic Locus Control
A Cas-based targeting system fused with light-sensitive receptors induces controlled protein clustering at specific genomic loci.
- IRF5 Nuclear Localization Inhibition via Cell-Penetrating Peptide
Cell-penetrating polypeptides block IRF5 nuclear localization, reducing pro-inflammatory cytokine expression and side effects in systemic lupus erythematosus.
- Chimeric Antigen Receptors Using TNFRSF Transmembrane Domains
TNFRSF transmembrane domains in chimeric antigen receptors increase T cell persistence and cytolysis despite rapid post-infusion disappearance.
- Adenoviral Vector Packaging System Using Cre-Lox Excision
A packaging system integrates adenoviral genes into host cells to eliminate helper virus contamination during vector production.
- CD276-Targeting CAR T-Cell Therapy for Solid Tumors
Engineered chimeric antigen receptors bridge T-cells and solid tumors, overcoming limited chemotherapy effectiveness.
- CD21-Targeting CAR T-Cell Therapy for T-ALL
Engineering a CD21-specific binding domain enables selective recognition of T-ALL cells while sparing normal T-cells from fratricide.
- Modified CARs With Reduced ITAMs for T Cell Persistence
Removing specific ITAM motifs from CD3ζ chains prevents T cell exhaustion, sustaining immune responses against cancer targets.
- GPI-anchored Antigen Modification for Enhanced Immunogenicity
Replacing the GPI anchor with a transmembrane domain directs modified antigens to endosomes, resolving low immunogenicity caused by membrane anchoring.
- Armored CAR T Cells Secreting Bispecific Antibodies for p95HER2 Targeting
Armored CAR immune cells secrete bispecific antibodies to recruit T cells against p95HER2-expressing tumors.
- BCMA CAR T Cell Therapy with IL-1Ra Antagonist for Toxicity Control
Preliminary IL-1Ra administration mitigates cytokine release syndrome and neurotoxicity during BCMA CAR T cell therapy, enabling higher response rates.